louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05475977: Role of MSCT of Chest in Differentiation Between COPD Patients According to Their Smoking Status
Official title: Role of Multislice Computed Tomography (MSCT) Chest in Differentiation Between Chronic Obstructive Pulmonary Disease(COPD) Patients According to Their Smoking Status
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Patient Participation
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2022-07-27
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: COPD patients either smokers, ex-smokers or non-smokers

Brief summary: Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality all over the world. Smoking is considered as an important risk factor, but other risk factors are present. Around 30 % of patients with COPD are non-smokers.

Cessation of smoking in patients with COPD causes decreases the presence of micronodules and other criteria of CT chest.

In last few years, some researchers reported that cessation of smoking raise the apparent extent of emphysema. The cause is not obvious, but this paradoxical fall in lung density is thaught to be resulting from decrease in inflammation after smoking cessation.

CT chest criteria of COPD in active smokers, non-smokers and ex-smokers seem to be different.

So, comparison between CT chest Criteria of COPD in smokers, ex-smokers and non-smokers will be searched in this study to detect the role of multislice computed tomography (MSCT) chest in differentiation between COPD patients according to their smoking status.

Detailed description: Basic ethical principles of medical research; beneficence (do well), non-maleficence (do no harm), respect and distributive justice were implemented. The study will be carried out in accordance with the Declaration of Helsinki and the principles of good clinical practice.

Eligibility criteria: Inclusion Criteria:

1. All patients with chronic obstructive Pulmonary Disease.
2. Patients above 18 years.

Exclusion Criteria:

1. Patients with unclear smoking history.
2. Patients with active pneumonia.
3. Patients with acute COPD exacerbation.

Primary outcomes:
measure: Number of participants with criteria of severe COPD
timeFrame: 18 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Assiut University
name: Somaia Ahmad AbdAllah Ahmad, M.B.B.Ch
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06337877: Assessment of Sedation Depth Using Processed EEG in ICU Patients With ARDS Receiving Neuromuscular Blockade: A Prospective Observational Study"
Official title: Assessment of Sedation Depth Using Processed EEG in ICU Patients With ARDS Receiving Neuromuscular Blockade: A Prospective Observational Study"
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sedation Complication
Acute Respiratory Distress Syndrome Due to COVID-19
Anesthesia Awareness
Lead sponsor: Tepecik Training and Research Hospital
Sponsor class: OTHER
First posted: 2024-03-29
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Intensive care unit patients who has ARDS

Brief summary: "In intensive care units, therapeutic paralysis has been a routine treatment method for many years in a select group of patients. Sufficient and appropriate sedation in patients undergoing therapeutic paralysis is crucial to prevent awareness and reduce the risk of excessive sedation. Both inadequate and excessive sedation levels can be highly detrimental to the patient. Clinical assessment may not always provide accurate information regarding sedation depth. Recently, the frequency and workload of therapeutic paralysis treatment in intensive care units have increased due to COVID-19 pneumonia. Therefore, the investigators believe that inadequate sedation may be common in these patients. Processed electroencephalogram parameters such as bispectral index or patient state index (PSI), routinely used in operating rooms and intensive care units, are commonly used to indicate sedation depth. In this study, the investigators aimed to determine sedation levels in patients during paralysis, assess the prevalence of inadequate or excessive sedation, and observe the doses of sedatives and analgesics used."


Eligibility criteria: Inclusion Criteria:

* "Patients aged 18 years and older who have received continuous neuromuscular blocking agents for at least 24 hours."

Exclusion Criteria:

1. Patients under 18 years of age,
2. pregnant individuals
3. trauma patients,
4. intracerebral pathology
5. major bleeding
6. central nervous system diseases,
7. pre-existing poor neurological condition before admission to the intensive care unit,
8. inability to document continuous neuromuscular blocking agent infusion for at least 24 hours."

Primary outcomes:
measure: To determine the sedation levels of patients during paralysis
timeFrame: For patients undergoing therapeutic paralysis, over a 24-hour period,"
measure: The prevalence of inadequate or excessive sedation,
timeFrame: For patients undergoing therapeutic paralysis, over a 24-hour period,"
Secondary outcomes:
measure: Evaluation of Concordance Between Richmond Agitation-Sedation Scale (RASS),
timeFrame: The assessment process conducted immediately before the application of paralysis."
Other outcomes:
Locations:
city: İ̇zmi̇r
country: Turkey
facility: Aykut Saritaş
state: İzmir
Study officials:
References:
Clinical trial NCT02212977: Comparison of Topical Skin Adhesive to Subcuticular Suture Closure of Implantable Port Incisions
Official title: Comparison of Topical Skin Adhesive to Subcuticular Suture Closure of Implantable Port Incisions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Port-A-Cath Placement
Octylcyanoacrylate
Keywords: Port Catheter
Octyl 2-cyanoacrylate
2-octylcyanoacrylate
Lead sponsor: Duke University
Sponsor class: OTHER
First posted: 2014-08-11
Enrollment: 109
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hypothesis is that incision closure with octylcyanoacrylate is inferior to closure with stitches in Port a Cath patients, who, as a population, are at increased risk for complications. All adult patients who present for initial Port a Cath placement during the recruitment period will be eligible to participate in the study. Subjects will be randomized to either skin incision closure with standard stitches or closure with skin glue. Time to complete skin closure and costs of closure will be compared. Patients will be evaluated approximately one month and three months from the procedure to assess for complications of wound breakdown or infection, as well as for the appearance of the Port a Cath incision.


Eligibility criteria: Inclusion Criteria:

* All adult patients (≥18 years) who present for initial implantable port placement during the recruitment period will be eligible to participate in the study

Exclusion Criteria:

* Patients who cannot provide informed consent for the procedure will be excluded from the study.

Primary outcomes:
measure: Number of Participants With Complication of Wound Dehiscence
timeFrame: 3 months
measure: Number of Participants With Complication of Infection
timeFrame: 3 months
Secondary outcomes:
measure: Healing-incision Cosmesis Score by Visual Analogue Scale
timeFrame: 3 months
measure: Closure Time
timeFrame: Baseline
measure: Closure Materials Cost
timeFrame: Baseline
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
Study officials:
affiliation: Duke University
name: Charles Kim, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00148577: Pain Relief by Applying TENS on Acupuncture Points During the First Stage of Labour
Official title: Pain Relief by Applying Transcutaneous Electrical Nerve Stimulation (TENS) on Acupuncture Points During the First Stage of Labour: a Randomised Controlled Trial
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pain Relief at First Stage
Keywords: Pain Relief, TENS, Acupuncture Points
Lead sponsor: Chang Gung Memorial Hospital
Sponsor class: OTHER
First posted: 2005-09-08
Enrollment: 100
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE

Brief summary: We aimed to establish the reduction of labor pain by applying TENS at acupuncture points during the first stage of labour, to assess their efficacy, and to ascertain their acceptability.

Detailed description: We conducted a double-blind, placebo-controlled randomised trial involving healthy parturient at term pregnancy using TENS on 4 acupuncture points (Li 4 and Sp 6) (n=50) and the placebo group (n=50). Visual analogue scale (VAS) was used to assess the effect on pain before the application, 30 minutes and 60 minutes after TENS. The objective parameter of outcome was the score of VAS decreased in each groups. A post-partum questionnaire was given 24 hours later to evaluate the satisfaction and the use of this pain relieving method for the next delivery.

Eligibility criteria: Inclusion Criteria:

The inclusion criteria were:

* Voluntary informed participation to the study
* An initial wish to deliver without epidural analgesia
* Planned vaginal childbirth (non-obstetrical complicated pregnancy)
* Fetal vertex presentation
* Term pregnancy (\>37 weeks of gestation)
* Apply at 1st stage of labour and excluded if cervical dilatation \> 5 cm
* Age between 20 and 40 years
* Chinese speaking, capable to understand the study
* No experience of pain relief by systemic or epidural anesthesia in previous delivery
* No experience in acupuncture or TENS in other field
* Had no heart disease nor using pace-maker.

Exclusion Criteria:

* Cervical dilatation \> 5 cm
* Experience of pain relief by systemic or epidural anesthesia in previous delivery
* Experience in acupuncture or TENS in other field
* Had heart disease or using pace-maker

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Tao-Yuan
country: Taiwan
facility: Chang Gung Memorial Hospital
Study officials:
affiliation: Chang Gung Memorial Hospital
name: An-Shine Chao, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04146077: Active Surveillance for Low Risk Prostate Cancer
Official title: Active Surveillance Methodology for Low Risk Prostate Cancer
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Prostate Cancer
Prostate Adenocarcinoma
Keywords: prostate cancer
active surveillance
low oncological risk
Lead sponsor: I.M. Sechenov First Moscow State Medical University
Sponsor class: OTHER
Collaborators: name: Moscow Regional Research and Clinical Institute (MONIKI)
name: Pirogov Russian National Research Medical University
First posted: 2019-10-31
Enrollment: 100
Sex: MALE
Minimum age (years): 50
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Men with low risk prostate cancer, who gave informed consent to undergo active surveillance and to participate in this study, and had no previous treatment of prostate cancer or surgery at the prostate.

Brief summary: An active surveillance protocol for patients diagnosed low-risk prostate cancer will be held. We plan to use PSA (prostate-specific antigen) testing, DRE (digital rectal examination), TRUS (transrectal ultrasound), MRI (magnetic resonance imaging) and follow-up biopsies to monitor patients and detect cancer progression in time.


Eligibility criteria: Inclusion Criteria:

* prostate adenocarcinoma verified by at least 12 core biopsy
* patient must understand the sense of research, agree to participate and sign a form of agreement
* low oncological risk according to EAU (European Association of Urology) Guidelines: stage T1-T2a, PSA\<10 ng/ml, ISUP (International Society of Urological Pathologists score)=1 (Gleason score 3+3=6)
* not more than 33% cores with adenocarcinoma

Exclusion Criteria:

* previous treatment of prostate cancer
* other prostatic malignant neoplasms
* other oncological diseases
* treatment with 5-alfa-reductase inhibitors
* patient's refuse to continue study
* patient's desire to begin treatment

Primary outcomes:
measure: cancer progression
timeFrame: 5 years
Secondary outcomes:
measure: surgical treatment due to infravesical obstruction by BPH
timeFrame: 5 years
Other outcomes:
Locations:
city: Moscow
country: Russian Federation
facility: Institute for Urology and Reproductive Health, Sechenov University.
Study officials:
References:
Clinical trial NCT06276777: The Effect of Using Desensitizers Containing S-PRG In Treatment Of Dentin Hypersensitivity Over 6 Months: A Randomized Clinical Trial
Official title: The Effect of Using Desensitizers Containing S-PRG Versus Sodium Fluoride With Functionalized Tri-Calcium Phosphate In Treatment Of Dentin Hypersensitivity In Adult Patients Over 6 Months: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Dentin Hypersensitivity
Keywords: S-PRG
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-02-26
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to compare the effect of desensitizer containing S-PRG have similar effect as sodium fluoride with functionalized tri-calcium phosphate containing desensitizer in relieving dentinal hypersensitivity in adult patients for six months follow-up. patients will be asked to report pain degree on the visual analogue scale (VAS) along the follow up periods on both groups.


Eligibility criteria: Inclusion Criteria:

* Good oral hygiene.
* Cooperative patients who show interest to participate in the study and welling to sign the informed consent.
* Healthy patients with no history of previous systematic diseases that can affect their oral health.
* Normal and healthy gingival tissue.
* Teeth that have no cavitation or restorations.
* Patients with at least 20 natural permanent teeth and at least two teeth with a VAS score from 4 to 10.
* Anterior teeth.

Exclusion Criteria:

* Allergic to the ingredients used in the study.
* Gastrointestinal disorders (They have repeated vomiting attacks).
* Medically compromised (They cannot tolerate the procedures).
* Taking desensitizing treatment in the last 6 months (It affects the outcome).
* Taking anti-inflammatory drugs (It affects the hypersensitivity perception).
* Pregnant females (They complain from nausea and repeated vomiting attacks)
* Smokers (Smoking will affect the oral hygiene and periodontal health).

Primary outcomes:
measure: Dentin hypersensitivity reduction
timeFrame: assessment will be done immediately after the treatment then after 1 week, 4 weeks, 3 months and 6 months.
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Dentistry Cairo University
Study officials:
affiliation: Cairo University faculty of oral and dental medicine
name: Eman Omar, bachelor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06794177: The Effects of Dual Task Training with Different Task Priorities on Physical Performance and Cognitive Status in Patients with Parkinson's Disease
Official title: Investigation of the Effects of Dual Task Training with Different Task Priorities on Physical Performance and Cognitive Status in Patients with Parkinson's Disease
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Parkinson&#39;s Disease (PD)
Dual-task
Balance
Walking
Mobility
Cognition
Lead sponsor: Hacettepe University
Sponsor class: OTHER
Collaborators: name: Gazi University
name: Saglik Bilimleri Universitesi
First posted: 2025-01-27
Enrollment: 30
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study was planned to investigate and compare the effects of variable and fixed priority dual task training on balance, walking skills, mobility and cognition in patients with Parkinson's disease.


Eligibility criteria: Inclusion Criteria:

* Having agreed to participate in the research after being given detailed information about the research.
* Having been diagnosed with Parkinson's disease by a specialist neurologist according to the UK Brain Bank criteria
* Being in stage 1-3 according to Hoehn \& Yahr
* Being 40 years of age or older

Exclusion Criteria:

* Having a neurological condition other than Parkinson's disease
* Cognitive impairment
* Have undergone deep brain stimulation surgery
* Having a visual, auditory or perceptual problem
* Having any orthopedic, rheumatological or other disease that may affect walking and balance.

Primary outcomes:
measure: Hoehn and Yahr Scale
timeFrame: Baseline, 6 weeks
measure: Unified Parkinson's Disease Rating Scale
timeFrame: Baseline, 6 weeks
measure: Berg Balance Scale
timeFrame: Baseline, 6 weeks
measure: Functional Reach Test
timeFrame: Baseline, 6 weeks
measure: Single Leg Stance Test
timeFrame: Baseline, 6 weeks
measure: Four Square Step Test
timeFrame: Baseline, 6 weeks
measure: 10 Meter Walk Test
timeFrame: Baseline, 6 weeks
measure: Figure-of-Eight Walk Test
timeFrame: Baseline, 6 weeks
measure: 3-Meter Backward Walk Test
timeFrame: Baseline, 6 weeks
measure: Timed Up and Go Test
timeFrame: Baseline, 6 weeks
measure: Unified Parkinson's Disease Rating Scale, Part 2
timeFrame: Baseline, 6 weeks
measure: Dual Task Questionnaire
timeFrame: Baseline, 6 weeks
measure: Trail Making Test
timeFrame: Baseline, 6 weeks
measure: Stroop Test
timeFrame: Baseline, 6 weeks
measure: Symbol Digit Modalities Test
timeFrame: Baseline, 6 weeks
measure: Word List Generation
timeFrame: Baseline, 6 weeks
measure: Tampa Scale for Kinesiophobia
timeFrame: Baseline, 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Sağlık Bilimleri Üniversitesi, Gülhane Fizyoterapi ve Rehabilitasyon Fakültesi
city: Ankara
country: Turkey
facility: Gazi Üniversitesi Tıp Fakültesi Nöroloji Anabilim Dalı
Study officials:
References:
Clinical trial NCT06934577: Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2
Official title: Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine- SIGHT 2: A Pragmatic Randomized Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Eye Diseases
Visual Impairment
Glaucoma
Keywords: Eye disease screening
Glaucoma detection
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: Centers for Disease Control and Prevention
First posted: 2025-04-18
Enrollment: 900
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants meeting inclusion criteria who are 18 years of age or older will be randomized to either 1) control group: standard optometric examination or 2) intervention group: technology-enhanced eye disease screening protocol. Randomization will be stratified by disease risk in two strata: 1) those with and without diabetes, and 2) those \< age 40 and those ≥ age 40. After stratification, participants will be block randomized to the control or intervention arm.
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: To compare eye disease detection rates at a Federally Qualified Health Center between a technology-enhanced protocol and standard optometric clinical examination for three of the leading causes of blindness: glaucoma, diabetic retinopathy, and visually significant cataract.

Detailed description: See study protocol.

Eligibility criteria: Inclusion Criteria:

Speak English or Spanish

Exclusion Criteria:

1) significant eye pain (2) sudden decrease in vision within one week (3) binocular diplopia (4) cognitive impairment (5) pregnancy, or (6) previously declined participation

Primary outcomes:
measure: Rate of vision threatening eye disease (glaucoma/suspected glaucoma, visually significant cataract, diabetic retinopathy)
timeFrame: Visit 1(day 1)
measure: Rate of glaucoma/suspected glaucoma
timeFrame: Visit 1 (Day 1)
measure: Rate of visually significant cataract
timeFrame: Visit 1(day 1)
measure: Rate of diabetic retinopathy
timeFrame: Visit 1(day 1)
Secondary outcomes:
measure: Visual Function
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Flint
country: United States
facility: Hamilton Optometry Clinic
state: Michigan
Study officials:
affiliation: University of Michigan
name: Paula Anne Newman-Casey, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01907477: Identification of Serum and/or Plasma Biomarkers for the Diagnosis Prognosis and/or Prediction of Invasive Mycosis in Neutropenic Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neutropenic Patients
Lead sponsor: Centre Hospitalier Universitaire Dijon
Sponsor class: OTHER
First posted: 2013-07-25
Enrollment: 500
Sex: ALL
Minimum age (years): 14
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The aim of the present work is to study the protein expressions profiles of neutropenic patients (with a high risk of invasive mycosis) who developed - versus who did not develop invasive mycosis (principally aspergillosis and candidosis) in order to identify biomarkers for the diagnosis, prognosis and /or prediction of invasive mycosis.


Eligibility criteria: Inclusion Criteria:

* - Patients with malignant haemopathy who received chemotherapy likely to lead to severe neutropenia (PN\<500/mm3) for a foreseeable period of 10 days.
* Patients aged 14 years or older (no upper age limit)
* Patients with malignant haemopathy who received an autologous marrow graft.
* Patients with severe idiopathic medullar aplasia (PN\<500/mm3) who need to be hospitalised for at least 10 days consecutively (with or without immunosuppressant treatment).
* Patients who have provided written informed consent to participate in this study.

Exclusion Criteria:

* Patients who received an allograft of marrow or hematopoietic stem cell transplant (given that these patients carry a risk of aspergillosis, which in most cases appears after medullar recovery, they will not be included in the study).
* Patients who received an autologous hematopoietic stem cell transplant (given that the duration of the neutropenia is often less than 10 days).
* Patients who do not meet the inclusion criteria
* Persons not covered by the national Health Insurance Agency

Primary outcomes:
measure: the variability of protein profiles
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Dijon
country: France
facility: CHU de Dijon
Study officials:
References: